Full Title
A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial (MM1OA-EA02) (CIRB)Purpose
Researchers want to see if adding gilteritinib to two other drugs works better than the other drugs alone for leukemia. The people in this study include older and unfit adults with acute myeloid leukemia (AML). In addition, their AML has a mutation (change) in a gene called FLT3.
Azacitidine turns on genes that help control cell growth. It is given intravenously (by vein) or by injection.
Venetoclax blocks Bcl-2, a protein needed for cancer cell survival. Gilteritinib blocks a growth signal that helps certain cancer cells multiply. Venetoclax and gilteritinib are taken orally (by mouth).
If you join this study, you will be randomly assigned to get azacitidine and venetoclax alone (standard treatment), or to get the standard treatment with gilteritinib.
Contact
For more information and to see if you can join this study, please call Dr. Aaron Goldberg’s office at 646-608-3752.